View in EDS

A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.

Saved in:
Bibliographic Details
Title: A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.
Authors: Jones S; Sarah Cannon Research Institute, Nashville, TN., Falchook G; Sarah Cannon Research Institute at HealthOne, Denver, CO., Graff S; HCA Midwest Kansas City, Kansas City, KS., Arrowsmith E; Tennessee Oncology, PLLC, Nashville, TN., Kilari D; Medical College of Wisconsin, Milwaukee, WI., Gersten TA; Florida Cancer Specialists and Research Institute East, Wellington, FL., Hussein M; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute North, Tavares, FL., Percent I; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute South, North Port, FL., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN.; SCRI Oncology Partners, Nashville, TN.
Source: The oncologist [Oncologist] 2026 Jul 22. Date of Electronic Publication: 2026 Jul 22.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42485262
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jones+S%22">Jones S</searchLink>; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Falchook+G%22">Falchook G</searchLink>; Sarah Cannon Research Institute at HealthOne, Denver, CO.<br /><searchLink fieldCode="AU" term="%22Graff+S%22">Graff S</searchLink>; HCA Midwest Kansas City, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Arrowsmith+E%22">Arrowsmith E</searchLink>; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Kilari+D%22">Kilari D</searchLink>; Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Gersten+TA%22">Gersten TA</searchLink>; Florida Cancer Specialists and Research Institute East, Wellington, FL.<br /><searchLink fieldCode="AU" term="%22Hussein+M%22">Hussein M</searchLink>; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute North, Tavares, FL.<br /><searchLink fieldCode="AU" term="%22Percent+I%22">Percent I</searchLink>; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute South, North Port, FL.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, TN.; SCRI Oncology Partners, Nashville, TN.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 Jul 22. <i>Date of Electronic Publication: </i>2026 Jul 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42485262
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyag279
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jones S
      – PersonEntity:
          Name:
            NameFull: Falchook G
      – PersonEntity:
          Name:
            NameFull: Graff S
      – PersonEntity:
          Name:
            NameFull: Arrowsmith E
      – PersonEntity:
          Name:
            NameFull: Kilari D
      – PersonEntity:
          Name:
            NameFull: Gersten TA
      – PersonEntity:
          Name:
            NameFull: Hussein M
      – PersonEntity:
          Name:
            NameFull: Percent I
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 07
              Text: 2026 Jul 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1